Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy

Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Medicines...

FOLD : 13.80 (-0.04%)
Amicus Therapeutics (FOLD) Down 7.5% Since Last Earnings Report: Can It Rebound?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FOLD : 13.80 (-0.04%)
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020

Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September:...

FOLD : 13.80 (-0.04%)
Amicus' (FOLD) Q2 Earnings Surpass Estimates, Revenues Miss

Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.

EBS : 101.63 (+2.54%)
ALIM : 5.05 (unch)
FOLD : 13.80 (-0.04%)
ACIU : 4.78 (-1.34%)
Amicus Therapeutics (FOLD) Reports Q2 Loss, Misses Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 23.08% and -0.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

FOLD : 13.80 (-0.04%)
Amicus Therapeutics: 2Q Earnings Snapshot

CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Monday reported a loss of $52.5 million in its second quarter.

FOLD : 13.80 (-0.04%)
Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates

Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of

FOLD : 13.80 (-0.04%)
Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

NVAX : 113.56 (+10.86%)
HALO : 26.06 (+1.24%)
FOLD : 13.80 (-0.04%)
ICPT : 40.42 (+1.66%)
RETA : 93.83 (-8.67%)
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August...

FOLD : 13.80 (-0.04%)
Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FOLD : 13.80 (-0.04%)
New Strong Sell Stocks for July 31st

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

CME : 166.78 (+1.74%)
KAMN : 38.41 (-0.18%)
FOLD : 13.80 (-0.04%)
HAYN : 17.37 (-0.52%)
INDB : 50.12 (-0.73%)
Look for Shares of Amicus Therapeut to Potentially Pullback after Yesterday's 2.82% Rise

Amicus Therapeut (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $14.87 to a high of $15.70. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high...

FOLD : 13.80 (-0.04%)
Amicus Therapeut Rises 4.29% on Heavy Volume: Watch For Potential Pullback

Amicus Therapeut (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $12.77 to a high of $13.90. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high...

FOLD : 13.80 (-0.04%)
Why Is Amicus Therapeutics (FOLD) Up 10.9% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FOLD : 13.80 (-0.04%)
Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 41 Annual Global Healthcare Conference,...

FOLD : 13.80 (-0.04%)
Amicus Therapeut Set to Possibly Pullback After Yesterday's Rally of 2.24%

Amicus Therapeut (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $12.32 to a high of $12.77. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high...

FOLD : 13.80 (-0.04%)
Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders

Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that its 2020...

FOLD : 13.80 (-0.04%)
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.00% and 5.80%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

FOLD : 13.80 (-0.04%)
Amicus Therapeutics: 1Q Earnings Snapshot

CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $88.9 million in its first quarter.

FOLD : 13.80 (-0.04%)
Amicus Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates

Galafold 1Q2020 Revenue of $60.5 Million Reflects Continued Strong Adoption in All Key Global Regions, On Track to Achieve 2020 Revenue Guidance of $250M-$260M

FOLD : 13.80 (-0.04%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar